The AMCP Managed Care & Specialty Pharmacy Annual Meeting is all about adapting and thriving in a world of constant change and challenge. This April, in revolutionary Boston, we will bring together the experts, decision makers and thought leaders at the forefront of managed care pharmacy and health care: all for one great meeting.

- Educational sessions that deliver rich content for those who manage and evaluate drug therapies, develop and manage networks, and work with medical managers and information specialists in managed care settings.

- Networking events that allow all the facets of our field to connect, discuss, learn, and problem-solve in a dynamic, collegial setting.

- Informal gatherings and meet-ups that enhance the attendee experience and afford plenty of opportunities for achieving your meeting goals.

It’s the Managed Care and Specialty Pharmacy Event of the Year! Join us for springtime in Boston.
Welcome to AMCP’s Partnership Forum, “Managing Care in the Wave of Precision Medicine.” We are grateful that you have taken time out of your busy schedule to join us on this important topic.

Mapping the human genome in the 1990s and early 2000s promised to usher in a new era of targeted therapies based on a patient’s unique genetic makeup. Today that prediction has become a reality. More and more precision treatments and cures are available that were inconceivable only a few short years ago.

The challenge before us is how to ensure products, tailored for individual patients, will be widely adopted under the current health care system, which focuses on delivering care to large populations. In practice, precision medicine requires tests and screenings that may not be routine. As such, data needed to evaluate or customize a therapy are not always easy to obtain.

With your help over the next day and a half, we will address such challenges and seek recommendations to better integrate precision medicine within managed care settings. During this Partnership Forum, we will identify best practices and recommendations to inform AMCP discussions with key policymakers, regulators and stakeholders on the topic of precision medicine. Other issues we will examine include:

- Technology needed to support the efficient application of precision medicine.
- Evidentiary standards needed by managed care pharmacy to make informed formulary and coverage decisions for precision medicine.
- Benefit designs and reimbursement strategies needed to integrate precision medicine, including the development of new care models.
- Potential ethical challenges and the impact on population and utilization management tools.
- Defining success in managing precision medicine, including development of outcomes-based quality measures.

To address these issues we have assembled an outstanding group of thought leaders from across the health care spectrum. This diversity of expertise and perspective has become a hallmark of our forums, which have addressed many pressing challenges over the years, including value in oncology, value-based contracting, and patient reported outcomes. I fully expect the same result for precision medicine. Your work will have a direct bearing on AMCP’s 8,000 members, who design and implement pharmacy benefits for more than 270 million Americans.

Thank you again for your participation. I also would like to extend a warm thank you to our sponsors who made this event possible: Amgen, Foundation Medicine, Genentech, Gilead, MedImpact, National Pharmaceutical Council, Precision for Value, Sanofi, Takeda and Xcenda. I look forward to a productive event.

Sincerely,

Susan A. Cantrell, RPh, CAE
Chief Executive Officer
Academy of Managed Care Pharmacy
<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30am – 8:30am</td>
<td>BREAKFAST</td>
</tr>
<tr>
<td>8:30am – 9:15am</td>
<td>WELCOME &amp; INTRODUCTIONS</td>
</tr>
<tr>
<td>9:15am – 10:15am</td>
<td>PANEL DISCUSSION – Current Initiatives in Precision Medicine</td>
</tr>
<tr>
<td></td>
<td>This panel will discuss current initiatives in precision medicine including goals and objectives, as well as progress to date.</td>
</tr>
<tr>
<td>10:15am – 10:45am</td>
<td>PRESENTATION – Precision Medicine in Practice</td>
</tr>
<tr>
<td></td>
<td>This presentation will provide a real world example of the application of precision medicine to optimize patient outcomes.</td>
</tr>
<tr>
<td>10:45am – 11:00am</td>
<td>BREAK</td>
</tr>
<tr>
<td>11:00am – 12:00pm</td>
<td>PANEL DISCUSSION – Understanding the Evidence Needed for Precision Medicine</td>
</tr>
<tr>
<td></td>
<td>This panel will discuss the evidentiary needs for precision medicine from the perspective of a managed care organization. The panel will also discuss how patient and provider perspectives should be considered when defining the evidentiary standards for formulary placement, coverage reimbursement, analysis of real world evidence for precision medicines, and clinical decision making.</td>
</tr>
<tr>
<td>12:00pm – 1:00pm</td>
<td>NETWORKING LUNCH</td>
</tr>
<tr>
<td>1:00pm – 2:30pm</td>
<td>BREAKOUT SESSION #1 – Identifying the Evidentiary Standards for Precision Medicine from the Perspective of Managed Care Pharmacy</td>
</tr>
<tr>
<td></td>
<td>During this breakout session, forum participants will identify the evidentiary standards needed by managed care pharmacy to make informed formulary and coverage decisions for precision medicine.</td>
</tr>
<tr>
<td>2:30pm – 3:30pm</td>
<td>PANEL DISCUSSION – Perspectives on the New Wave of Information</td>
</tr>
<tr>
<td></td>
<td>Panelists will discuss their experiences sifting through new sources of information for what is clinically meaningful for precision medicine decision making. Panelists will discuss what operational or technical solutions exists to find meaningful change with small samples of patients.</td>
</tr>
<tr>
<td>3:30pm – 3:45pm</td>
<td>BREAK</td>
</tr>
<tr>
<td>3:45pm - 5:00pm</td>
<td>BREAKOUT SESSION #2 – Overcoming Challenges with Data Collection &amp; Interoperability for Precision Medicine</td>
</tr>
<tr>
<td></td>
<td>During this breakout session, forum participants will develop strategies for overcoming challenges and barriers to robust data collection and information gathering for precision medicine. Forum participants will develop recommendations for flexible clinical trial designs, pharmacovigilance of precision medicine to assess their safety, and opportunities to increase patient engagement.</td>
</tr>
<tr>
<td>5:00pm – 5:30pm</td>
<td>AGREEMENT ON CONSENSUS RECOMMENDATIONS FOR DAY 1 &amp; WRAP-UP</td>
</tr>
<tr>
<td>5:30pm – 7:00pm</td>
<td>NETWORKING RECESSION</td>
</tr>
</tbody>
</table>
### DAY 2 – FRIDAY, DECEMBER 8, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am – 8:00am</td>
<td>BREAKFAST</td>
</tr>
<tr>
<td>8:00am – 8:15am</td>
<td>WELCOME &amp; SUMMARY OF DAY 1</td>
</tr>
<tr>
<td>8:15am – 9:45am</td>
<td>BREAKOUT SESSION #3 – Innovating Benefit Design &amp; Reimbursement Strategies for Precision Medicine</td>
</tr>
<tr>
<td></td>
<td>During this breakout session, forum participants will consider innovative benefit designs and reimbursement strategies for the coverage of precision medicines, including the development of models for precision medicines given that traditional population health models utilized by managed care pharmacy may not be applicable. Forum participants will consider the impact of precision medicine on current managed care pharmacy utilization management tools. In addition, forum participants will consider coverage and reimbursement for a pharmacist or other health care provider’s time associated with analysis and evaluation of a patient’s genomic sequencing and subsequent recommendations to the patient’s medication regimen. Finally, Forum participants will discuss mechanisms for defining success with precision medicines, including the development of outcomes-based quality measures.</td>
</tr>
<tr>
<td>9:45am – 10:00am</td>
<td>BREAK</td>
</tr>
<tr>
<td>10:00am – 11:30am</td>
<td>BREAK SESSION #4 – Tackling the Legal &amp; Regulatory Barriers to the Adoption of Precision Medicine</td>
</tr>
<tr>
<td></td>
<td>During this breakout session, forum participants will identify legal and regulatory barriers to the adoption of precision medicine from a managed care pharmacy perspective. Forum participants will discuss areas such as The Health Insurance Portability and Accountability Act (HIPAA) vs The Genetic Information Nondiscrimination Act (GINA), differing regulatory pathways for FDA approval, non-discriminatory formulary design laws, and other pertinent areas. Forum participants will develop recommendations for how AMCP can advocate for clarification and modernization of these laws and regulations to advance the adoption of precision medicine.</td>
</tr>
<tr>
<td>11:30am – 12:00pm</td>
<td>PRIORITIZING FUTURE DISCUSSIONS</td>
</tr>
<tr>
<td>12:00pm – 12:15pm</td>
<td>AGREEMENT ON CONSENSUS RECOMMENDATIONS FOR DAY 2</td>
</tr>
<tr>
<td>12:15pm – 12:30pm</td>
<td>NEXT STEPS &amp; CLOSING REMARKS</td>
</tr>
<tr>
<td>12:30pm</td>
<td>NETWORKING LUNCH</td>
</tr>
</tbody>
</table>
Transforming the language of life into vital medicines

At Amgen, we believe that the answers to medicine’s most pressing questions are written in the language of our DNA. As pioneers in biotechnology, we use our deep understanding of that language to create vital medicines that address the unmet needs of patients fighting serious illness — to dramatically improve their lives.

For more information about Amgen, our pioneering science and our vital medicines, visit www.amgen.com.
Clifford Goodman, PhD
Senior Vice President & Director
Lewin Center for Comparative Effectiveness Research

Clifford Goodman is a senior vice president at The Lewin Group and has 30 years of experience in a wide range of health care areas, including health technology assessment; evidence-based health care; comparative effectiveness research; and studies pertaining to health care innovation. His recent work has also been wide ranging and includes such areas as oncology, cardiovascular disease, diabetes, blood disorders, HIV/AIDS, biosimilars, pharmacogenomics, personalized medicine, value frameworks, and value-based contracting. Clifford is an internationally recognized health policy issues moderator and facilitator of expert panels, health industry advisory boards, and workshops. He served as Chair of the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC, 2009-12) for the US Centers for Medicare and Medicaid Services (CMS), as well as President of the professional society, Health Technology Assessment International (HTAi, 2011-13). He is a Fellow of the American Institute for Medical and Biological Engineering (AIMBE).
Foundation Medicine is leading a transformation in cancer care, where each patient’s treatment is informed by a deep understanding of the molecular changes that contribute to their disease. By providing comprehensive genomic profiles, a suite of support and technology services, and an expertise driven by a knowledge base of over 90,000 patients, we are able to help oncology care teams discover more treatment options for their patients.

See more at foundationmedicine.com
Forum Participants

Rachel Anhorn, PharmD
Director, Payer Policy and Health Outcomes
Foundation Medicine
Rachel Anhorn is a director of payer policy and health outcomes on the Payer Relations and Reimbursement Team at Foundation Medicine. She leads the development of US HEOR initiatives and is focused on payer education about the unique clinical value of comprehensive genomic profiling. Her professional interests include helping to shape health care policy to promote the value of oncology diagnostics and genomically matched precision treatment to improve outcomes and cost-effectiveness of cancer care for all stakeholders.

Kristine Ashcraft, MBA
Chief Executive Officer
YouScript
Kristine Ashcraft is a trained molecular biologist and is CEO of YouScript. She has worked in the precision medicine field since 2000 and has authored multiple publications on the clinical and economic benefits of pharmacogenomic testing. She has been interviewed by numerous media outlets, including The New York Times and NBC Nightly News, and has spoken at South by Southwest, the American Society of Human Genetics, and numerous precision medicine conferences. She is committed to being a catalyst in the adoption of precision medicine.

Mary Beattie, MD, MAS
Senior Medical Director, Precision Medicine, BioOncology, US Medical Affairs
Genentech
Mary Beattie is a senior medical director for precision medicine at Genentech, working in BioOncology for US Medical Affairs. Before joining Genentech in 2012, she was a professor of medicine at the University of California, San Francisco (UCSF), studying hereditary breast and ovarian cancer. Mary majored in chemistry at Duke, graduated from the Ohio State University College of Medicine, and completed internal medicine residency training at UCSF. Mary leads the Genentech MyPathway trail, which studies multiple molecules and tumors based on molecular profiles.

Elise Berliner, PhD
Director, Technology Assessment Program
Agency for Healthcare Research and Quality (AHRQ)
Elise Berliner, Ph.D., is the director of the technology assessment program, providing technology assessments to the Centers for Medicare & Medicaid Services (CMS) to inform Medicare coverage decisions and other policy issues. Prior to joining AHRQ, she worked as a consultant to pharmaceutical and medical device companies on cost-effectiveness and outcomes research, technology assessment and reimbursement planning. She also has several years of experience in research and development at a number of innovative medical technology companies.
For 30 years, Gilead has worked to develop medicines that address areas of unmet medical need for people around the world.

Our portfolio of medicines and pipeline of investigational drugs include treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.

Every day we strive to transform and simplify care for people with life-threatening illnesses.
Forum Participants

Patricia Bourne, PharmD  
**Director, Medical Sciences**  
Gilead Sciences  
Patricia Bourne is currently director of medical sciences for the Managed Care and Government Accounts Medical Scientist (MCGA MS) team at Gilead Sciences. She provides oversight to the MCGA MS team responsible for interfacing with payers and specialty pharmacies across multiple therapeutic areas involving medical affairs and HEOR activities. She has owned and managed a successful retail pharmacy and has worked as a clinical hospital and consulting long-term care pharmacist. She has also held positions in managed care as director of pharmacy services and operations.

Michael Ciarametaro, MBA  
**Vice President of Research**  
National Pharmaceutical Council  
Michael Ciarametaro plays a key role at the National Pharmaceutical Council in developing and delivering its portfolio of health policy and health outcomes projects. He has 13 years of healthcare industry experience with pharmaceutical manufacturers and payers. Most recently, he was a senior research manager at Evidera, where he designed and led a variety of qualitative and quantitative studies across multiple health care industries and stakeholders. He has also served as a financial analysis manager at WellPoint NextRx and as lead staff at Noblis.

Gregory Daniel, PhD, MPH  
**Deputy Director**  
Duke-Margolis Center for Health Policy  
Gregory Daniel directs the DC-based office of the Center and leads the Center’s pharmaceutical and medical device policy portfolio, which includes developing policy and data strategies for improving development and access to innovative pharmaceutical and medical device technologies. This includes post-market evidence development to support increased value, improving regulatory science and drug development tools, optimizing biomedical innovation, and supporting drug and device value-based payment reform. He is also a Clinical Professor in Duke’s Fuqua School of Business.

Lisa Egbonu-Davis, MD, MPH, MBA  
**Vice President, Global Head, Patient Outcomes and Solutions**  
Sanofi  
Lisa serves as strategic lead for building patient centered support programs, services and tools that enhance medication adherence and improve healthcare outcomes. Lisa utilizes expertise in data analytics and behavioral science to catalyze the development, measurement, adaptation, and dissemination of effective interventions. Previously, Lisa served as Pfizer’s Vice President of Medical Affairs and Vice President of Global Outcomes Research, developing evidence from clinical trials, observational studies, and “real world” analyses to support product value assessment.
How do you create value and drive results for your pharmacy program?

Learn how an aligned pharmacy benefit business model truly focused on the quality and value of healthcare – not revenue – can create value and drive results through low-net cost.

To see how MedImpact can help you develop clinical strategies to better manage costs and care, contact us at info@medimpact.com
Forum Participants

Matthew Feltman, RPh
Chief Operating Officer/General Manager
Kroger Prescription Plans

Matthew Feltman is responsible for creating and managing the strategic business plan for Kroger Prescription Plans and for the overall results in the areas of clinical, marketing, sales, operations, and financial oversight. Matthew joined Kroger as a pharmacist in 1997 and since then has held a series of leadership positions. Matthew holds a BS in pharmacy from Ohio Northern University and certificates in medication therapy management and community-based pharmacogenomics.

Karen Geary, MHA, RPh
Vice President, Strategy & Innovation
MedImpact Healthcare Systems

Karen Geary is a managed care pharmacy executive with over 25 years of experience in pharmacy benefit management, specialty pharmacy, Medicare prescription drug plan, and health administration. Karen has served in various capacities at MedImpact for over 12 years. Her current focus area is in innovation to address the expanding role of the pharmacist and the engagement of the consumer. She has previously held leadership positions in benefit design, product development, and cost management with Aetna and UPMC Health Plan.

Stuart Goldberg, MD
Chief Scientific Officer
COTA

Stuart Goldberg is chief scientific officer at COTA, an oncology-focused data and analytics company, and associate clinical professor at Rutgers New Jersey Medical School. Stuart has used Medicare and claims databases to redefine the incidence and complications related to myelodysplastic syndromes and has reviewed observational databases to foster adherence with evidence-based CML monitoring guidelines. Most recently, he has used the observational COTA database to explore rates and implications of EGFR mutational testing among community oncologists and cost-effectiveness of genomic profiling in lower-risk breast cancer.

Jennifer Hall, PhD
Chief, Institute for Precision Cardiovascular Medicine
American Heart Association

Jennifer Hall serves as chief of The Institute for Precision Cardiovascular Medicine for the American Heart Association and was a past chair of the Functional Genomics and Translational Biology Council of the American Heart Association. She has also served on other national and international committees, including the National Heart Lung and Blood Parent Committee, the AHA Steering Committee, and the DNA Framingham Committee. Jennifer holds a PhD in physiology from the University of California, Berkeley, and has completed postdoctoral fellowships at Stanford and Harvard schools of medicine.
Can We Help Patients Through Innovative Payer-Pharma Agreements?

When payers and biopharmaceutical companies collaborate on value-based agreements, it can increase patient access to innovative treatments.

But there are operational, communications and regulatory issues that make it challenging for payers and biopharmaceutical companies to develop these agreements.

It’s time to work on solutions to these challenges for the benefit of patients and our entire health care system.

Learn more about this important topic by visiting NPC’s website at www.npcnow.org.
Can We Help Patients Through Innovative Payer-Pharma Agreements?

When payers and biopharmaceutical companies collaborate on value-based agreements, it can increase patient access to innovative treatments. But there are operational, communications and regulatory issues that make it challenging for payers and biopharmaceutical companies to develop these agreements.

It’s time to work on solutions to these challenges for the benefit of patients and our entire health care system.

Learn more about this important topic by visiting NPC’s website at www.npcnow.org.
We live here and work here. No wonder we know all the roads leading to commercial success.

The landscape may seem foreign to some, but as former payers ourselves we see insights others miss. Unlike those who offer up little but theories and unproven opinions on market access drivers, Precision for Value provides real-world payer perspectives. Combine these with insights from academia, and you can be confident you’ll get what decision makers desire most—relevant value propositions, innovative reimbursement strategies, and precise pull-through that lead to commercial success for your brand. precisionforvalue.com
Forum Participants

Summerpal Kahlon, MD
Director, Care Innovation
Oracle
Summerpal Kahlon serves as director of care innovation at Oracle, with a focus on delivering technological infrastructure to support individualized care at the intersection of population health and precision medicine. He has a background in electronic health records, health data exchange, mHealth, and telemedicine, in addition to time in community practice as an adult infectious diseases specialist in Florida. He is currently on staff at the Orlando VA Medical Center and is an assistant professor of medicine with the University of Central Florida College of Medicine.

Nicholas Keeling, MS
PhD Candidate/Research Assistant
University of Mississippi School of Pharmacy/St. Jude Children’s Research Hospital
Nick Keeling’s research focus as a PhD candidate has been on the translational science of pharmacogenetics and the preemptive testing model, and he has presented at several NIH-sponsored multicenter research consortia that support these protocols, such as CPIC and IGNITE, as well as commercial interests. At St. Jude, Nick works with the PG4KDS preemptive pharmacogenetics protocol. Nick looks forward to future work in developing strategies for more efficient implementation of genomic and other medical technology innovations.

Jill Kolesar, PharmD, MS
Professor
University of Kentucky
Jill Kolesar is professor of pharmacy at the University of Kentucky and holds administrative positions at the Markey Cancer Center as the director of the Precision Medicine Center, co-chair of the Molecular Tumor Board, and co-leader of the Developmental Therapeutics Program. She is a member of the graduate faculty in the College of Pharmacy, a member of the Markey Cancer Center, and holds a joint appointment in internal medicine in the College of Medicine.

Laura M. Koontz, PhD
Personalized Medicine Staff
US Food and Drug Administration
Laura Koontz is a member of the personalized medicine staff at the US Food and Drug Administration in the Center for Devices and Radiological Health. She was the director of policy for the Ovarian Cancer National Alliance, where she oversaw congressional and regulatory policy. Laura was also an ASHG-NHGRI Genetics and Public Policy fellow from 2012-2013 and worked in the US House of Representatives. Laura holds a PhD in biochemistry, cellular, and molecular biology from the Johns Hopkins University School of Medicine.
Over the years, Sanofi has evolved to meet the new challenges of healthcare worldwide. Today, Sanofi is a global healthcare leader focused on patients. We listen to their needs, treat them, and provide support to them. Through our diversified portfolio of medicines, vaccines and innovative therapeutic solutions, we strive to protect the health and meet the needs of the world’s 7 billion people.
SANOFI FOCUSED ON PATIENTS’ NEEDS
Over the years, Sanofi has evolved to meet the new challenges of healthcare worldwide. Today, Sanofi is a global healthcare leader focused on patients. We listen to their needs, treat them, and provide support to them. Through our diversified portfolio of medicines, vaccines and innovative therapeutic solutions, we strive to protect the health and meet the needs of the world’s 7 billion people.

More than 18,000 employees in the United States
More than 120 locations across North America
A comprehensive offering of medicines, vaccines and innovative services all over the world

For more information:
www.sanofi.com – www.sanofi.us

Forum Participants

Jay McKnight, PharmD, BCPS  
Market Vice President, Pharmacy Clinical Strategies  
Humana Pharmacy Solutions  
Jay McKnight leads Humana’s Pharmacy Clinical Strategies team. His responsibilities include improving member outcomes, members’ quality of life, and reducing the cost of healthcare. He also leads Humana's pharmacy clinical trend and drug pipeline management processes, as well as formulary strategy. He is a board certified pharmacotherapy specialist and received his Doctor of Pharmacy from the University of Kentucky.

Kristen Migliaccio-Walle  
Director, GHEOR  
Xcenda  
Kristen Migliaccio-Walle is a Director in global health economics & outcomes Research at Xcenda. In this role, she specializes in value assessment frameworks and economic evaluation across a broad range of global HEOR engagements. Prior to joining Xcenda in 2012, she was Senior Decision Scientist at the Institute for Clinical and Economic Review (ICER) and spent over 16 years with a large global scientific organization where she developed her methodological and therapeutic expertise in disease course modeling, risk assessment, and economic evaluations.

Franziska Moeckel  
Assistant Vice President, Personalized Health  
Inova  
Franziska Moeckel oversees the strategy development for genomic services and test integration at Inova’s Center for Personalized Health and Translational Medicine Institute. She is the co-creator of MediMap®, Inova’s pharmacogenomic testing program and its first trademarked, commercial product line.

Robert Pannone, BS, PharmD  
Executive Director, Health Outcomes and Pharmacoeconomics (HOPE)  
Amgen  
Robert Pannone is the executive director of Amgen’s Health Outcomes and Pharmacoeconomics (HOPE) Medical Liaison group. He manages a field-based team of regional medical liaisons who focus on health outcomes, health policy, and value-based economic decision making for Amgen clients and thought leaders. Current responsibilities for this team include full in-line portfolio; launch and pipeline support, with emphasis on health outcomes; comparative effectiveness; and health policy.
Better Health, Brighter Future

There is more that we can do to help improve people’s lives. Driven by passion to realize this goal, Takeda has been providing society with innovative medicines since our foundation in 1781.

Today, we tackle diverse healthcare issues around the world, from prevention to care and cure, but our ambition remains the same to find new solutions that make a positive difference, and deliver medicines that help as many people as we can, as soon as we can.

With our breadth of expertise and our collective wisdom and experience. Takeda will always be committed to improving the future of healthcare.
Better Health, Brighter Future
There is more that we can do to help improve people’s lives. Driven by passion to realize this goal, Takeda has been providing society with innovative medicines since our foundation in 1781. Today, we tackle diverse healthcare issues around the world, from prevention to care and cure, but our ambition remains the same to find new solutions that make a positive difference, and deliver medicines that help as many people as we can, as soon as we can. With our breadth of expertise and our collective wisdom and experience, Takeda will always be committed to improving the future of healthcare.

Takeda Pharmaceuticals America, Inc. www.takeda.com
USD/TAK/17/0001

Forum Participants

David Parker, PhD
Senior Vice President, Diagnostics Solutions
Precision for Medicine

David Parker leads Precision’s diagnostics solutions consulting practice and provides strategic advisory services to the firm’s diagnostics and biopharma clients. David has over 30 years of experience in health care, including 21 years as a strategy consultant focused on advanced diagnostics, personalized medicine, and targeted therapies. His expertise has resulted in numerous successful product launches, guided major investment, and acquisition decisions.

Chip Parkinson
Executive Vice President, Reimbursement Strategies
Myriad Genetics

Chip Parkinson joined Myriad Genetics in 2016. Previously, he was president of OmedaRx and led the company to become the first pharmacy benefit manager to be recognized by the Institute for Clinical and Economic Review for demonstrated excellence in the practice of health technology assessment. Chip has also served as chief pharmacy officer of Regence Blue Cross Blue Shield health plans, where he managed health plans in Utah, Washington, Oregon, and Idaho.

Emanuel Petricoin, PhD
Chief Science Officer
Perthera

Emanuel Petricoin is co-founder and chief scientific officer of Perthera and has been the co-director of the Center for Applied Proteomics and Molecular Medicine at George Mason University since 2005, where he is a university professor. He is a co-inventor on 40 patents and has authored over 390 peer-reviewed publications and invited reviews. He is a senior editor for Cancer Epidemiology Biomarkers & Prevention and has received numerous awards, including the NIH Director’s Award, GAP50 Top Virginia Entrepreneurs, and the Harvard University Leading Edge Award, and is a Kentucky colonel.

Daryl Pritchard, PhD
Senior Vice President, Science Policy
Personalized Medicine Coalition

Daryl Pritchard is senior vice president of science policy at Personalized Medicine Coalition and works to increase awareness and understanding of personalized medicine; identify and address barriers to the adoption of personalized medicine into the health care system; and develop and promote appropriate clinical, health care infrastructure, regulatory, and payment policies. Daryl has also served as the director of policy research at the National Pharmaceutical Council and as director of research programs advocacy and personalized medicine at the Biotechnology Industry Organization.
In a marketplace where demands for data and differentiation are high, choose a market access partner that can turn your hard work into an inspiring story.

*Choose Xcenda.*

With scientific rigor as a foundation, along with innovative thinking and creative expertise, Xcenda helps uncover and transform evidence into an impactful value proposition that matters to payers and maximizes access to your product.

Together, let’s inspire success.

Visit us at www.xcenda.com
Forum Participants

Daryl Spinner, PhD, MBA  
Managing Director, Real-world Value and Strategy  
Evidera
Prior to working at Evidera, Daryl was Senior director of managed care and reimbursement at Courtagen Life Sciences, a next-generation sequencing-based genetic testing company. At Courtagen, he developed and led companywide market access and commercial strategies, including engagement with HTA agencies, payers, providers, and customer groups. Prior to Courtagen, he was an Associate Practice Lead and Principal Consultant at Quintiles Advisory Services, where his specialty included value demonstration and global market access of emerging health technologies.

Robin Turpin, PhD  
Value Evidence Lead  
Takeda
Robin Turpin received her PhD in Social Psychology and was a distinguished fellow with the National Institute of Disability and Rehabilitation Research. Robin worked for hospital and healthcare systems, including a period with JCAHO to lead performance metric testing. With 30 years of experience in healthcare evaluation, she has co-authored more than 100 books, book chapters, and journal articles on health economics and population health management. She has held academic appointments with Loyola University Chicago and Northwestern University Medical School.

Jeffrey Waldron  
Executive Director  
Personalized Medicine Connective
Jeff Waldron is executive director of the Personalized Medicine Connective, a non-profit firm that is developing strategic collaborations to drive adoption of personalized medicine by integrating the silos of the healthcare industry. Their initial clinical focus is on melanoma, where they are developing new interventions to improve patient outcomes along with a health economics model to prove value. Previously, Jeff worked in the office of the president of Aetna directing strategic and operational planning.

Todd Winey  
Senior Advisor  
InterSystems Corporation
Todd Winey is has over 25 years of healthcare IT experience spanning payer and provider information technology. He brings a strategic perspective to healthcare IT that is eclectic. His career in healthcare IT has evolved along with the industry itself, from early coding and reimbursement software, claims adjudication, document management systems, acute clinical systems, to interoperability, medical device connectivity and health information exchange. His current focus is on the intersections of healthcare data and interoperability across the markets of clinical laboratories, imaging, genomics and IoT.
Accessible
Convenient
Choices

The Online Learning Platform
for Continuing Education and Training,
Uniquely Designed for the Managed Care Professional

AMCP Learn is your one-stop shop for processing your continuing pharmacy education credit from AMCP meetings and conferences, as well as the site of a whole new selection of online learning programs. Whether you choose face-to-face learning, online programs, or a mix of both, AMCP Learn is the resource created just for you.

- **Top-Rated Sessions Recorded Live at AMCP Meetings and Conferences**
  These programs allow you to keep up with the latest findings presented at AMCP’s largest gatherings of managed care professionals.

- **AMCP CE Webinars and Symposia**
  Original programming created specifically for AMCP, these grant-supported webinars and symposia cover a wide range of therapeutics and disease states.

- **Certificate Programs like Fundamentals of Managed Care Pharmacy**
  In-depth certificate programs are designed to give participants a thorough background in specific subjects. *Fundamentals of Managed Care Pharmacy* is AMCP Learn’s most popular program, offering 15 hours of high-level content from the field’s founding thought leaders. Available in a professional version and a non-accredited student version.

Whether you are looking for a brief, hour-long presentation or a multi-part program, AMCP Learn has the continuing education programming you need to stay current.

Visit [http://amcplearn.org today](http://amcplearn.org)!
Kristine Bordenave, MD, FACP
Corporate Medical Director
Humana, Inc.

Kristine Bordenave is a Corporate Medical Director for Humana’s Central Medicare Teams and the PPS/SIU divisions, with a significant background in CMS, fraud/waste/abuse, tailored quality improvement, utilization management, research and healthcare system redesign. She brings over twenty years in clinical leadership, research and direct patient care to her work. She is driven by a desire to ensure efficient, high quality resources to support the health of present and future generations.

Lena Chaihorsky, BS
Vice President, Payer Innovation
Alva10

Leveraging her background in biology and mathematics, Lena works with payers to develop diagnostics for high-risk patient populations. She most recently led the reimbursement strategy of QIAGEN’s global molecular diagnostics portfolio and has broad experience in diagnostics commercialization, sales, contracting, and reimbursement. She has personally performed every step in the reimbursement spectrum of a diagnostic, and takes both a product-specific and portfolio-wide view of the healthcare products she brings to payers.

Erick Lin, MD, PhD
Medical Director
Blue Cross Blue Shield Association

Erick Lin serves as a Medical Director for the Evidence Street™ platform and currently leads the Precision Medicine strategy at Blue Cross Blue Shield Association (BCBSA). Previously, he was Manager and Senior Manager of Medical Affairs at Illumina, Inc. and Director of Medical Affairs at Ambry Genetics. He completed his MD and PhD training at Northwestern University’s Feinberg School of Medicine and residency training in pathology and fellowship in Molecular Genetic Pathology at the UCLA David Geffen School of Medicine.
ACADEMY OF MANAGED CARE PHARMACY STAFF

Susan A. Cantrell, RPh, CAE
Chief Executive Officer

Mary Jo Carden, RPh, JD
Vice President, Government & Pharmacy Affairs

Charlie Dragovich, BS Pharm
Vice President, Strategic Alliances & Corporate Services

Fahim Faruque,
PharmD Candidate 2018
Pharmacy Affairs Associate

Caroline Huber, MPH
Writer, Associate Director & Research Scientist, Precision Health Economics

Lauren Lyles, PharmD
Manager of Pharmacy Affairs & New Practitioner Programs

Zain Madhani
Program Coordinator, Government & Pharmacy Affairs

Beth O’Brien, CMP
Director, Meetings and Conventions

Noreen Matthews, BSN, MBA
Program Management American Medical Communications

Soumi Saha, PharmD, JD
Director, Pharmacy and Regulatory Affairs

Ruby Singh, PharmD, BCPS
Vice President, Education & Training

Tricia Lee Wilkins, PharmD, MS, PhD
Director, Pharmacy Affairs

THANK YOU
To our distinguished participants and guests.
The Academy of Managed Care Pharmacy looks forward to holding more partnership forums focused on issues of greatest importance to our 8,000 members, the more than 270 million Americans covered by the pharmacy benefit, and other health care stakeholders.

AMCP Academy of Managed Care Pharmacy®
Developed by the Understanding Comparative Effectiveness Research (CER) is the key to efficiently and effectively assessing the value of new treatments using multiple types of studies to inform medical policy and decision-making.

Online tools and training through the CER Collaborative, a joint program developed by the Academy of Managed Care Pharmacy, International Society for Pharmacoeconomics and Outcomes Research, and National Pharmaceutical Council, have been updated and enhanced. Enroll in the CER Certificate Program and gain:

- Expert knowledge in evidence evaluation
- Skills for applying research evaluation tools to assess recent clinical and formulary reviews
- A robust, interactive, online learning environment designed for hands-on practice using case studies

The program is made up of five online modules and one final interactive peer workshop—the live session can be presented online or in person at designated events. The CER Certificate Program allows participants to earn 19 continuing pharmacy education credit hours.

Visit www.amcp.org/CERCertificate today for more information.

About the Collaborative—AMCP, ISPOR, and NPC formed the CER Collaborative to provide greater uniformity and transparency in the evaluation and use of evidence for coverage and health care decision-making with the ultimate goal of improving patient outcomes.
Developed by the
Understanding Comparative Effectiveness Research (CER) is the key to efficiently and effectively assessing the value of new treatments using multiple types of studies to inform medical policy and decision-making.

Online tools and training through the CER Collaborative, a joint program developed by the Academy of Managed Care Pharmacy, International Society for Pharmacoeconomics and Outcomes Research, and National Pharmaceutical Council, have been updated and enhanced. Enroll in the CER Certificate Program and gain:

- Expert knowledge in evidence evaluation
- Skills for applying research evaluation tools to assess recent clinical and formulary reviews
- A robust, interactive, online learning environment designed for hands-on practice using case studies

The program is made up of five online modules and one final interactive peer workshop—the live session can be presented online or in person at designated events. The CER Certificate Program allows participants to earn 19 continuing pharmacy education credit hours.

Visit www.amcp.org/CERCertificate today for more information.

About the Collaborative—AMCP, ISPOR, and NPC formed the CER Collaborative to provide greater uniformity and transparency in the evaluation and use of evidence for coverage and health care decision-making with the ultimate goal of improving patient outcomes.

The Academy of Managed Care Pharmacy wishes to thank the following organizations for their generous support of this AMCP Partnership Forum.